Japan’s SoftBank may have renewed interest in combining its Sprint with Deutsche Telekom T-Mobile US
but a deal between the No. 3 and No. 4 US wireless carriers may not make it past US regulators, antitrust experts and industry watchers said.
SoftBank is prepared to give up control of Sprint to T-Mobile, people familiar with the matter told Reuters on Friday. The companies are expected to begin negotiations in April after the Federal Communications Commission’s auction of airwaves concludes.
But two and a half years ago, SoftBank abandoned talks to acquire T-Mobile for Sprint amid opposition from US antitrust regulators.
It is hard to know how the new administration will view such a deal since President Donald Trump’s comments on antitrust have so far been populist, in contrast to the less skeptical view that past Republican administrations have taken of mergers, legal experts said.
“I am of the camp that that will not happen even in a Trump administration,” Christopher Marangi, co-chief investment officer at GAMCO Investors, said on the prospect of a deal. “That kind of merger means lots of job cuts in the US”
Job creation is a key platform for Trump. He has also been sharply critical of companies that have moved manufacturing operations to Mexico and elsewhere.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas